AbbVie Earnings: Can Skyrizi and Rinvoq Replace Humira?

465.02BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US00287Y1091
CUSIP
00287Y109
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
128.44
PEG Ratio
0.43
Book Value
-3.77
Dividend Share
6.74
Dividend Yield
2.56%
Earnings Share
2.05
Wall Street Target Price
268.68
EPS Estimate Current Year
14.12
EPS Estimate Next Year
16.30
EPS Estimate Current Quarter
2.6676
EPS Estimate Next Quarter
3.7409
Most Recent Quarter
-
Revenue TTM
62,819,000,320
Gross Profit TTM
45,246,001,152
EBITDA
29,915,000,832
Profit Margin
5.79%
Return On Assets TTM
10.03%
Return On Equity TTM
62.25%
Revenue Per Share TTM
35.501
Qtly Revenue Growth YOY
12.40%
Diluted Eps TTM
2.05
Qtly Earnings Growth YOY
-46.20%
Trailing PE
128.44
Forward PE
18
Price Sales TTM
7.4053
Price Book MRQ
50.4573
Enterprise Value Revenue
8
Enterprise Value EBITDA
31
257.79
0.66%55.31
0.62%130.24
0.29%158.52
0.00%46.92
-9.03%425.07
-5.03%156.60
-1.11%169.64
-1.02%1150.00
-0.53%440.00
-0.50%Curated watchlists where ABBV is featured.
AbbVie Earnings: Can Skyrizi and Rinvoq Replace Humira?
AbbVie shares fell after six-session winning streak
AbbVie said to be nearing a $10.9B deal to buy Apogee Therapeutics
Week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM - Seeking Alpha
AbbVie says not in talks to buy Revolution Medicines - report
Revolution Medicines jumps on report AbbVie nears takeover